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ABSTRACT 
 
Role of Protein Phosphatase-2A in Regulating Monocyte Activation by Soluble 
and Crystalline Uric Acid in Gout 
by Sandy ElSayed 
 
Gout is a chronic inflammatory disease caused by the phagocytosis of monosodium urate 
monohydrate (MSU) crystals by monocytes/macrophages resulting in downstream expression 
and production of interleukin-1 beta (IL-1β) and chemokines.  The activation of monocytes by 
MSU crystals involves the priming of monocytes with danger signals e.g. lipopolysaccharide 
(LPS) or soluble uric acid (UA), crystal phagocytosis and subsequent NLRP3 inflammasome 
activation and conversion of pro-IL-1β to active IL-1β.  Protein-phosphatase-2A (PP2A) is a 
serine/threonine phosphatase that plays an important role in cell growth and inflammation.  The 
prodrug Fingolimod (FTY720) and its phosphorylated active metabolite (p-FTY720) activate 
intracellular PP2A.  We hypothesized that monocyte activation by MSU crystals is mediated by a 
reduction in intracellular PP2A activity and restoring PP2A activity reduces MSU-induced 
inflammation in monocytes.  We aimed to investigate the role of PP2A in regulating monocyte 
priming and activation by MSU crystals and evaluate whether intracellular PP2A activation 
exerts an anti-inflammatory effect in MSU-stimulated monocytes.    
  
Human THP-1 monocytes were primed with a combination of UA and LPS.  MSU stimulation 
was performed for 4-6 hours and MSU crystal phagocytosis, PP2A activity, IL-1β expression 
and production were studied in primed and unprimed monocytes.  We performed PP2A 
knockdown in THP-1 monocytes and evaluated the impact of PP2A attenuation on IL-1β 
  VI 
expression and production in unprimed THP-1 monocytes.  Time-dependent intracellular PP2A 
activation in response to FTY720 or p-FTY720 treatments was studied and we evaluated the 
impact of p-FTY720 treatment on IL-1β expression and production in MSU stimulated human 
monocytes. 
 
Priming with UA+LPS increased MSU phagocytosis and IL-1β expression and production in 
monocytes.  This effect was associated with a reduction in intracellular PP2A activity.  PP2A 
knockdown increased IL-1β expression and production. FTY720 and p-FTY720 increased 
intracellular PP2A activity in monocytes.  p-FTY720 treatment reduced IL-1β expression and 
production in UA+LPS pre-treated monocytes following MSU stimulation mediated by an 
increase in PP2A activity with no alteration in PP2A gene expression.   
 
In summary, UA and LPS enhanced MSU phagocytosis, expression and production of IL-1β via 
a reduction in PP2A activity.  Pharmacological restoration of PP2A activity exerted an anti-
inflammatory effect.  We conclude that PP2A is a novel therapeutic target for gout treatment. 
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1. Introduction 
       1.1. Background and significance 
 
Gout is a prevalent inflammatory arthritis that affects the articular joints (mainly the 
metatarsophalangeal and knee joints) owing to the deposition of insoluble uric acid crystals 
in soft tissues causing pain and inflammation (1).  In the early history of medical writing, it 
appeared in the medical records and constituted a challenge to physicians.  Management of 
gout symptoms has improved with the availability of anti-inflammatory agents and urate 
lowering therapy, but a significant proportion of gout patients still have suboptimal outcomes 
(2).  The overall prevalence of gout in general population is 1-4% and it is more common in 
men (3-6%) than women (1-2%).  In populations above 80 years old, the prevalence rises to 
10% in men and 6% in woman. Gout affects 2.68 in 1,000 persons annually (3). The 
incidence of gout is constantly increasing worldwide and about 3-10% of gout patients are 
not adequately managed causing treatment failure gout (refractory gout) which can’t be 
controlled by conventional therapies (4,5). 
 
The hallmark of gout is the precipitation of monosodium urate monohydrate (MSU) crystals 
contributed to by an increase in serum uric acid levels (1).  Gout flares are characterized by 
self-limiting acute inflammation that lasts 2-3 days (6) interspersed between the low-grade 
inflammatory condition that is chronic gout (7).  Hyperuricemia is defined as a uric acid 
blood level above 6.5 mg/dL.  While hyperuricemia is a risk factor for gout, the relationship 
between hyperuricemia and gout is more complex.  Many individuals have hyperuricemia 
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without gout or even formation of urate crystals while approximately 5% of patients with 
hyperuricemia (serum uric acid above 9 mg/dL) advance to gout (8). 
 
Current acute gout treatment modalities include colchicine, corticosteroids and non-steroidal 
anti-inflammatory drugs (NSAIDs).  Colchicine prevents the activation of macrophages and 
subsequently the NLRP3 inflammasome.  It also inhibits the production of chemotactic 
factors, MCP-1 and IL-8.  However, the onset of colchicine’s clinical effect is slow and is 
associated with significant toxicities which limits its use in acute flares of gout (9,10).  The 
most common side effects of colchicine are gastrointestinal symptoms such as diarrhea 
reported in 23-77% of patients. Aplastic anemia has also been associated with exposure to 
colchicine.  The elderly and patients with renal or hepatic dysfunctions are at increased risk 
of developing these toxicities.  Colchicine has clinically significant drug-drug interactions 
with CYP3A4 inhibitors such as erythromycin.  NSAIDs are used in acute gout flares owing 
to their inhibition of cyclooxygenase-2 (COX-2) and downstream production of 
prostaglandins.  However, they have a number of side effects.  Gastrointestinal side effects 
could be minor as dyspepsia or severe as ulcers and perforations occurring in about 10% of 
patients. They also reduced kidney function in 1-5% of patients. They are associated with 
increased risk of cardiac events especially in patients with cardiovascular diseases. Other 
treatments include corticosteroids, which cause dysphoria, mood disorders, hyperglycemia, 
immune suppression and fluid retention. This makes the treatment of acute gout in patients 
with diabetes and hypertension with glucocorticoids challenging (11). The use of biologics 
like IL-1β receptor antagonist is still being evaluated.  Notably, none of the current 
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treatments provide a gout cure.  Therefore, optimal gout management remains as an unmet 
clinical need. 
      1.2. Gout pathogenesis is a multi-step process initiated by tissue-resident macrophages. 
 
In synovial joints, the synovial membrane is composed of two layers; the first layer is thin 
and highly cellular containing synovial macrophages and synovial fibroblasts.  Synovial 
fibroblasts produce hyaluronic acid and lubricin to establish an extracellular matrix to 
support the synovium. Macrophages are low in number in healthy synovial joints. When 
hyperuricemia leads to precipitation of MSU crystals in joints, MSU crystals are 
phagocytosed by macrophages resulting in the production of proinflammatory cytokines, 
which enhances synovial recruitment of additional immune cells leading to inflammation 
(12).  The effect of precipitated MSU crystals on the macrophages composes the first trigger 
of the inflammasome.  The cellular recognition of MSU crystals occurs through toll-like 
receptors (TLRs), especially TLR2 and TLR4 (13).  This leads to the production and 
secretion of pro-inflammatory cytokine, interleukin-1 beta (IL-1β), which recruits more 
inflammatory cells and amplifies the inflammatory response (14).  MSU crystals mediate 
their effect after being phagocytosed by stimulation of nicotinamide adenine dinucleotide 
phosphate (NADP) oxidase leading to the generation of reactive oxygen species (ROS) and 
activation of nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) 
inflammasome (15).   
 
The innate immune system produces an initial rapid inflammatory response in response to 
invading pathogens. This occurs when innate immune receptors recognize pathogen-related 
products as an antigen in order to subsequently eliminate those pathogens through their 
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engulfment or production of inflammatory cytokines.  Innate immune receptors are also 
known as pattern recognition receptors (PRRs) and they are present on cell surface and in 
cytoplasm. Toll-like receptors (TLRs) are an important group of PRRs.  TLRs are located on 
immune cells surfaces and play an essential role in mediating the host’s defense against 
pathogens. In humans, TLRs are activated by different Pathogen-Associated Molecular 
Patterns (PAMPs) including lipopolysaccharide as is the case with TLR4 and lipopeptide 
(Pam3CSK4) as is the case with TLR2.  TLRs are integral membrane receptors (type 1) with  
an N-terminal ligand recognition exterior domain, one transmembrane helix and a C-terminal 
cytoplasmic signaling domain also known as toll/interleukin receptor domain figure 1(16).  
 
 
 
 
 
 
 
 
Figure 1 Structure of toll-like receptors (TLRs).  The general structure of TLRs include: 1) An N-terminal 
exterior domain for ligand recognition 2) one transmembrane domain 3) A C-terminal intracellular signaling 
domain (similar to toll/interleukin domain) (11). 
 
Signaling of TLRs starts with the detection and binding of PAMPs by the extracellular 
domain.  When TLR is bound, Myeloid Differentiation 88 (MyD88) recruits IL-1R 
associated Kinase Protein (IRAK-1), IRAK-4 and TNF-α Receptor-Associated Factor 6 
(TRAF6) to make a receptor complex.  IRAK-1 causes ubiquitination of TRAF6 and 
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mediates activation of TGF-β-activated kinase 1 (TAK1) 
which is needed for NF-kB and Mitogen-Activated Protein 
Kinase (MAPK) activation. Activated TAK1 results in 
phosphorylation of IkB Kinase (IKK) and MAPK Kinase 6 
resulting in degradation of the NF-kB inhibitor, IkBα. This 
leaves NF-kB free to translocate to the nucleus so it can 
regulate gene expression.  NF-kB is composed of p50 and 
p65 subunit proteins, which are held in the cytoplasm by the 
inhibitory IkBα subunit. NF-kB is stimulated by many 
inflammatory signals including cytokines, MSU crystals and 
the inflammatory-stimuli induced phosphorylation-dependent 
degradation of IkBα that allows the translocation of NF-kB 
to the nucleus to mediate inflammation and decrease 
apoptosis.  The TLR signaling also includes MAPKs which 
are three types: ERK, JNK and p38 which can be activated 
separately or together.  ERK and p38 are essential for 
production of pro-inflammatory cytokines as TNF-α and IL-1 
(figure 2) (17,18).  Since phosphorylation is a critical step in 
activation of TLR-NF-kB pathway for the activation of NF-
kB, phagocytosis and recognition of MSU crystals by the 
TLR receptors leading to pathway protein phosphorylation could be due to the suppression of 
the activity of intracellular protein phosphatase 2A (PP2A). 
Figure 2 Toll-like Receptor 
(TLR) Signaling Pathway.  
The signaling pathway is 
initiated by binding of 
ligands to TLR receptor 
resulting in activation of 
MyD88 and recruitment of 
IRAK and TRAF6 to make 
a receptor complex. This 
receptor complex 
phosphorylates IKK.  IKK 
degrades inhibitory IkB 
releasing NF-kB.  Active 
NF-kB is translocated to the 
nucleus causing 
transcription of 
proinflammatory cytokines 
(17). 
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Pathogenesis of gout is a two-step process that begins with the NLRP3 inflammasome which is a 
multi-protein complex composed of NLR protein, adapter ASC (apoptosis-associated speck-like 
protein containing a caspase recruitment domain) and pro-caspase-1. Activation of 
inflammasome occurs initially through stimulation of TLR/MyD88 and NF-κB pathway by MSU 
crystals leading to transcription of pro-IL-1β gene, while the second step is the assembly of the 
multi-protein complex composed of NLR protein, ASC and pro—caspase-1 following activation 
by pathogen associated molecular patterns (PAMPs) and/or damage associated molecular 
patterns (DAMPs).  Subsequently, caspase-1 cleaves pro-IL-1β to mature IL-1β, which is 
biologically active and is released extracellularly.  The activation pathway of macrophages by 
MSU crystals is shown in figure 3.  In addition, MSU cause secretion of ATP and activation of 
P2X7 receptor causing efflux of potassium extracellularly which contributes to inflammasome 
activation (19). TLR4 plays an important role in gout as IL-1β production decreased significantly 
in acute gouty arthritis patients after blockage of the receptor using anti-TLR4 antibody (20).  
Priming of the TLR4 receptor may occur through the effect of PAMPs, DAMPs, 
lipopolysaccharide (LPS) or uric acid (in soluble or crystalline form). 
 
Uric acid (urate) crystals deposited in the joint cavity are phagocytosed by synovial macrophages 
leading to production of pro-inflammatory cytokines such as IL-1ß and TNF-α. While well-
differentiated macrophages can engulf MSU crystals without initiating an inflammatory 
response, less-differentiated monocytes produce increased levels of inflammatory cytokines: 
IL-1β, TNF-α, IL-6 and IL-8.  An acute gout attack is of a self-limiting episode as it resolves 
from hours to days after macrophages uptake and remove of crystals hence reducing macrophage 
activation and release of chemokines.  Furthermore, macrophages remove apoptotic cell bodies, 
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produce TGF-β and removes IL-1 to stop inflammation. Terminating acute attack includes 
production of anti-inflammatory cytokines, breakdown of pro-inflammatory cytokines, reduction 
of expression of receptors of inflammatory cytokines on leukocytes (2,20). 
 
 
 
 
 
 
 
IL-1 is a large family of cytokines (cell signaling proteins) that play a role in innate immune 
responses for defense against pathogens. They increase the expression of adhesion factors on 
immune cells to increase their efflux to the site of inflammation. IL-1β is synthesized through 
Figure 3 Production of IL-ß following NLRP3 Activation in response to 
monosodium urate crystal challenge.  The steps of the pathogenesis are 
summarized as: 1) Phagocytosis of MSU and stimulation of NADPH oxidase 
leading to production of ROS and activation of NLRP3 inflammasome. 2) 
Secretion of ATP to interact with purinergic receptor P2X7 on pannexin-1 
channels leading to potassium efflux and lower intracellular potassium that can 
also lead to NLRP3 activation. 3) Interaction of MSU with TLRs and 
activation of MyD88-and NF-κB pathway leading to transcription pro-IL-1β 
gene. 4) Finally, caspase-1 cleaves pro-IL-1β to IL-1β, which is released 
extracellularly (19). 
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NF-kB transcription in the nucleus resulting in the production of the biologically inactive pro-IL-
1β polypeptide. Post-translational modification by caspase-1 cleaves pro- IL-1β to generate the 
mature pro-inflammatory cytokine IL-1β which is released extracellularly to bind to interleukin 1 
receptor type 1 (IL-1R1) with the 
help of the co-receptor  IL-1 
receptor accessory protein (IL-
1RAP) to make a trimeric 
complex. This results in 
recruitment of MyD88, Toll-
interacting protein (TOLLIP) and 
IRAK-4. A stable complex is 
created between IL-1β, IL-1R1, 
IL-1RAP, MyD88 and IRAK-4. 
This results in a downstream 
cascade of phosphorylation steps 
which result in NF-kB activation 
and release of the transcription factors inducing mRNA expression of hundreds of inflammatory 
cytokines including themselves through a positive feedback loop (figure 4) (21,22). 
 
1.3. The proinflammatory mechanism of soluble uric acid. 
 
Uric acid is recognized as a disease-associated molecular pattern (DAMP) released from dying 
cells.  The mechanism by which soluble uric acid (UA) causes inflammation is still debatable.  In 
some perspectives, uric acid acts as an antioxidant.  In others, it is a pro-oxidant molecule, which 
Figure 4 Interleukin-1 beta (IL-1β) signaling pathway.  Binding of 
IL-1β to its receptor activates the MAPK and ERK pathways 
resulting in Iκβ degradation and NF-κB nuclear translocation (17). 
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acts as a DAMP on TLRs activating the NF-kB signaling pathway. Also, it reduces the 
availability of nitric oxide and increases the production of reactive oxygen species, induces 
chemotaxis and stimulates NF-kB and MAPK pathways. Hyperuricemia (without MSU 
deposition) was highly associated with disorders such as hypertension and kidney disease which 
share the common factor of a ‘redox imbalance’ (16).  A popular theory posits that UA causes 
state changes in cellular redox and increases the production of ROS leading to NLRP3 activation 
and eventually production of IL-1β.  In one study, UA was also found to be responsible for 
increasing the production of IL-1β through the NLRP3 and MyD88 pathways (18).  In that study, 
bone marrow derived macrophages were incubated in the presence of UA alone or in 
combination with LPS for 24 hours. It was observed that the UA+LPS treatment induced higher 
IL-1β expression compared to control cells and cells stimulated with UA or LPS alone (23). 
 
1.4. Protein phosphatase-2A (PP2A) plays a key role in regulating intracellular 
inflammatory signaling pathways. 
 
In cells, one third of proteins’ functions are regulated by phosphorylation and that leads to 
control of various cell functions.  Based upon the physiological requirements of the cell, proteins 
shift between phosphorylated and dephosphorylated states using protein kinases and 
phosphatases (24).  The family of protein phosphatases is divided mainly into two groups named 
as protein serine/threonine phosphatases (PSPs) and phosphotyrosine phosphatase (PTPs).  PSPs 
include protein phosphatase-1 (PP1) and protein phosphatase 2A (PP2A) (25,26).  PP2A was 
found to be involved in critical processes regarding cellular growth, cell cycle, DNA replication, 
transcription and translation, cell proliferation, apoptosis, signal transduction, cell mobility and 
cytoskeleton dynamics which made it a major target for therapy in cancer, heart, 
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neurodegenerative diseases and diabetes research (25,26).  PP2A is a complex composed of three 
subunits: scaffold subunit (A), catalytic subunit (C) which can exist independently forming an 
active core dimer and a variable regulatory subunit (B) making a heterotrimer complex (27).  
Activation of PP2A leads to initiation of multiple signaling pathways leading to apoptosis in 
cancer, modulation of cell growth and survival. (figure 5) (28).  One study found that serum 
levels of proinflammatory cytokines TNF-α and IL-6 increased in PP2A knock out mice 
following challenge with LPS (29).  This was associated with increased phosphorylation in the 
MAPK pathways and the NF-κB pathway in bone marrow derived macrophages from knock out 
mice. Authors concluded that PP2A played an essential role in regulation of inflammation in the 
site of a septic insult through its targeting of MyD88 and Toll/IL-1R domain-containing adaptor 
(29).  Taken all evidence together, it is plausible to expect that activation of PP2A could 
lead to reduction of inflammation in gout. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Regulation of protein phosphatase-2A (PP2A) and its associated signaling pathways.  PP2A is composed 
of three subunits: structural, regulatory and catalytic.  PP2A regulates multiple pathways including p53, Wnt and 
AKT pathways (28). 
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1.5. Clinically-available PP2A activators show efficacy in models of inflammation. 
 Fingolimod (FTY720) is an oral treatment for 
multiple sclerosis.  Fingolimod is a prodrug that is 
converted to the active metabolite Fingolimod 
phosphate (FTY720-P) by the enzyme sphinogsine 
kinase (figure 6).  FTY720-P looks like the natural 
ligand sphingosine-1-phosphate (S1P), which is a 
lipid mediator present extracellularly to S1P 
cognate G protein-coupled receptors.  S1P subtype 
1 (S1P1) regulates the lymphocytes migration to 
circulation from lymphoid tissues and hence plays a 
major role in immunity.  When FTY720-P binds to 
S1P1 with high affinity, it induces the persistent 
internalization of the receptor and thus antagonizes 
S1P-driven migration of lymphocytes from 
lymphoid tissues. (30).  FTY720 was found to block 
the PP2A inhibitor protein SET and thereby 
enhancing the activity of PP2A figure 7 (31,32).  In one study, activation of PP2A with FTY720 
(2.5 µM) has either limited or prevented tissue injury and inflammation in injury models of acute 
respiratory distress syndrome (ARDS) leading to decreased production of the chemokine 
interleukin-8 (IL-8) (33,34). Therefore, FTY720-P can be used as a research tool to examine 
Figure 6 Phosphorylation of Fingolimod 
(FTY720) to Fingolimod phosphate (FTY720-P) 
and interaction with the S1P1 receptor. 
Figure 7 Activation of protein-phosphatse-2A by 
fingolimod (FTY720) via inhibition of SET 
protein (30). 
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whether activating PP2A leads to decreased inflammation in gout as illustrated by decreased 
production of IL-1β by MSU challenged monocytes/macrophages (35). 
 
2. Hypothesis 
UA and LPS prime peripheral blood monocytes resulting in enhancement of MSU crystal 
phagocytosis and downstream production of inflammatory cytokines and PP2A is a critical 
regulator of this priming effect. 
 
2.1. Aim 1: 
 
To examine the activating effect of UA and LPS on MSU crystal phagocytosis and downstream 
activation of NLRP3 inflammasome, NF-κB and IL-1β expression and production in THP-1 
monocytes and test whether this effect is associated with a reduction in intracellular PP2A 
activity. 
 
2.2. Aim 2: 
 
To study the role of PP2A in regulating crystal-induced inflammation in monocytes and evaluate 
the utility of a PP2A-activating drug, fingolimod phosphate (FTY720-P), in providing an anti-
inflammatory activity in MSU stimulated monocytes. 
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3. Materials and Methods 
Human monocytes (THP-1) 
 
Human monocyte cells (THP-1, ATCC, USA) were cultured in 10% FBS, 1% 
penicillin/streptomycin RPMI-1640 media and 2-Mercaptoethanol as per ATCC 
recommendation in T75 flask to a density of 1.5 × 106 cells/mL in 37°C and 5% CO2. 
 
 
3.1. Reagents 
 
Monosodium urate monohydrate (MSU) crystals 
 
Pyrogen-free MSU crystals (Invivogen, USA) were resuspended with sterile phosphate buffered 
saline (PBS) and maintained at 4oC. 
 
Fingolimod hydrochloride (FTY720)   
Fingolimod hydrochloride (5 mg; Cayman Chemical; catalog # 10006292, USA) were 
reconstituted with 1,000µL dimethyl sulfoxide (DMSO) to make a stock solution (14.5 mM) and 
stored at -20°C. At the time of experiment, an intermediate concentration of 500µM was made 
by adding 34.5µL from the stock solution to 965.5µL DMSO.  Subsequently, 5µL from the 
intermediate stock solution were added to each 1,000µl media in wells to make final 
concentration of fingolimod 2.5µM. 
 
Fingolimod phosphate (FTY720-P) 
Fingolimod phosphate (0.59 mg; Cayman Chemical; catalog # 10008639, USA) was 
reconstituted with 10mL dimethyl sulfoxide (DMSO) to make a stock concentration (152.2µM) 
 14 
and stored at -20°C.  To make a final concentration of 2.5µM, 16µL of reconstituted solution 
were added to each 1,000µL media in well. 
 
Uric Acid (UA) 
Uric acid (U2625-25G, Sigma-Aldrich, USA) was solubilized as a concentration of 50 mg/dL in 
warm serum-free RPMI 1640 media.  
 
3.2. Phagocytosis of FITC labeled fluorescent beads in primed monocytes 
 
Monocytes were seeded in 24-well plate (0.6x106 cells/well) and were primed using 50mg/dL 
uric acid and 10ng/ml LPS for 24 hours (36).  Latex beads-rabbit IgG-FITC complex (7.5µl/well; 
Phagocytosis Assay Kit, Cayman Chemicals) were added directly into respective wells and 
incubated for 4 hours at 37°C.  Our experimental groups included: control unprimed monocytes 
(± latex beads), and UA, LPS, UA and LPS-primed monocytes (+ latex beads).  To assess 
phagocytosis, cells were centrifuged for five minutes at 400xg, then they were resuspended in 
300µL assay buffer.  The proportion of monocytes that phagocytized fluorescent beads was 
assessed based on increased side scatter properties using BD FACSVerse Flow Cytometer.  
 
3.3. Phagocytosis of MSU crystals by primed monocytes 
 
Monocytes were seeded in 6-well plate (0.5x106 cells/well) as control (± MSU), and UA, LPS, 
UA and LPS (+ MSU).  Cells were primed using 50mg/dL uric acid and 10ng/ml LPS for 24 
hours (36).  This was followed by 4 hours treatment with MSU crystals (100µg/mL). Cells were 
collected, centrifuged for 3,000 rpm for five minutes.  The supernatant was discarded and cells 
were suspended in 300µL PBS.  Indirect assessment of MSU phagocytosis was determined by 
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analyzing the change in cell side-scatter distribution due to crystal phagocytosis using a flow 
cytometer (BD FACSVerse).  Two regions of interest were identified; P1 representing the 
monocyte population in the absence of MSU exposure and P2 representing the monocyte 
population with increased side scatter due to MSU phagocytosis.  MSU-positive cells were 
calculated as the ratio of cells in the P2 region to the sum of cells in the P1 and P2 regions.    
   
3.4. IL-1β gene expression in primed monocytes 
 
A total of 500,000 monocytes were plated per well in a 6-well plate.  Cells were primed with UA 
and LPS for 24 hours at 37°C as described above. Cells were treated with MSU crystals 
(100µg/mL) for 6 hours.  After incubation, cells were collected, centrifuged at 3,000 rpm for 5 
minutes to be pelleted.  The supernatant was collected and stored at -20°C while total RNA was 
extracted using trizol reagent (Thermo Fisher Scientific, USA) and mRNA concentrations were 
determined using Nanodrop One Microvolume UV-Vis spectrophotometer (Thermo Scientific, 
USA). cDNA was synthesized using iScriptTM cDNA Synthesis Kit (Biorad, USA).  qRT-PCR 
was done by QuantstudioTM 3 Real-Time PCR System (Thermo Fisher Scientific, USA) with 
TaqMan® Fast Advanced Master Mix (Life Technologies, USA).  The probes were labeled with 
6-carboxyfluorescein (6-FAM). The primers used in PCR are listed in Table 1.  The cycle 
threshold (Ct) values of the gene of interest were normalized with the value of GAPDH of the 
same sample, and the relative expression of each gene was analyzed using the 2-ΔΔCt method (37). 
 
Gene  Forward (5’ to 3’) Reverse (5’ to 3’) 
GAPDH ACTGGCGTCTTCACCACCAT AAGGCCATGCCAGTGAGCTT 
IL-1β TTGTTGCTCCATATCCTGTCC CACATGGGATAACGAGGCTT 
PP2Ac TCGTTGTGGTAACCAAGCTG AACATGTGGCTCGCCTCTAC 
 
Table 1 Primers used for gene amplification 
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3.5. IL-1β production by primed THP-1 monocytes 
 
Monocytes (500,000 cells per well) were seeded in 6-well plates and primed with UA and LPS 
for 24 hours as described above. Then, they were stimulated with MSU (100 μg/mL) for 6 hours.  
Media supernatants were collected and IL-1β concentration was measured using Human IL-
1beta/IL-1F2 Duoset ELISA kit (R&D Systems; DY201-05, USA). 
 
3.6. PP2A knockdown using protein phosphatase-2A catalytic subunit (PP2Ac) siRNA  
 
Monocytes (1.0x10-6 cells/well) were seeded in 6 well plates using Opti-MEMTM Reduced 
Serum Medium (Thermo Fisher; 31985088, USA) and labeled as control, PP2A siRNA and 
negative control. PP2CA siRNA (Thermo fisher Scientific; AM16708, USA) and SilencerTM 
Negative Control siRNA (Thermo fisher Scientific; AM4611, USA) were reconstituted and 
added to their respective wells at concentration of 3μM with 9μl of LipofectamineTM 3000 
Transfection Reagent (Invitrogen; L3000001, USA) in a total volume of 2500μl/well and 
transfection was left for 24 hours at 37oC. PP2A knockdown was confirmed using gene 
expression.  First, total RNA was extracted using trizol reagent (Thermo Fisher Scientific, USA) 
and mRNA concentrations were determined using Nanodrop One Microvolume UV-Vis 
spectrophotometer (Thermo Scientific, USA).  cDNA synthesis and qPCR assays were 
performed as described above.  The probes were labeled with 6-carboxyfluorescein (6-FAM). 
The primers used in PCR are listed in Table 1.  The cycle threshold (Ct) values of the gene of 
interest were normalized with the value of GAPDH of the same sample, and the relative 
expression of each gene was analyzed using the 2-ΔΔCt method.  The relationship between PP2A 
expression and PP2A activity was established by measuring PP2A activity following PP2A 
knockdown. After 24 transfecting THP-1 cells for 24 hours, transfected cells were collected, 
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centrifuged at 3,000 rpm for five minutes, pelleted and lysed using RIPA Buffer with protease 
inhibitor and then re-centrifuged at 14,000 rpm for ten minutes. The protein isolate was collected 
and stored at -80°C.  Protein levels were measured using Pierce™ BCA Protein Assay Kit 
(Thermo Fisher Scientific; 23225, USA).  A total of 5 μL of each sample was mixed with 195μL 
RIPA buffer and protease inhibitor in microcentrifuge tubes then 75μL were added in 96-well 
plates in duplicate wells.  Working reagent (75μl) were added to each well and mixed on shaker 
for 30 seconds then plate was covered and incubated at 37°C for 30 minutes. Absorbance was 
measured at 562nm.  After determining protein levels, 5μg/well protein was used to measure 
PP2A activity using the PP2A immunoprecipitation kit (Sigma Aldrich, USA).  Protein samples 
were added to 4μL anti-PP2A C subunit and 30μL protein A agarose slurry then the volume was 
brought to 120μL with the assay buffer. Samples were incubated on shaker for 3 hours at 4°C. 
Agarose beads were then washed 3 times with 400μL 1X TBS and once with 200μl assay buffer.  
A phosphopeptide substrate (40μL) were added to the beads and 20μL assay buffer. The mixture 
was incubated for ten minutes at 30°C on a shaking incubator then centrifuged and 25μL of 
supernatants were added to each well in 96-well plate in duplicates.  For color development, 
100μL of malachite green phosphate detection solution were added to each well. Absorbance 
was measured at 650nm.  
 
3.7. IL-1β expression and production in PP2Ac siRNA-treated THP-1 monocytes following 
incubation with MSU crystals 
Monocytes (1.0x10-6 cells/well) were seeded in 6 well plates using Opti-MEMTM Reduced 
Serum Medium (Thermo Fisher; 31985088, USA) and labeled as control (±MSU), PP2A siRNA 
and negative control (+MSU). PP2CA siRNA (Thermo fisher Scientific; AM16708, USA) and 
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SilencerTM Negative Control siRNA (Thermo fisher Scientific; AM4611, USA) were 
reconstituted and added to their respective wells at concentration of 3μM with 9μL of 
LipofectamineTM 3000 Transfection Reagent (Invitrogen; L3000001, USA) in a total volume of 
2,500μL/well and transfection was left for 24 hours at 37oC. MSU crystals (100μg/mL) were 
then added to their respective wells.  Cells were collected, centrifuged, pelleted and media 
supernatants were collected and IL-1β gene expression and media concentrations were 
determined as described above. 
 
3.8. Impact of FTY720 and FTY720-P treatments on intracellular PP2A activity in human 
THP-1 monocytes 
THP-1 monocytes (0.4x106 cells per well) were seeded in 6 well plates.  FTY720 (2.5μM) and 
FTY720-P (2.5μM) were added and cells were collected at 1 hour, 3 hours, 6 hours and 24 hours. 
PP2A immunoprecipitation and PP2A activities were determined as described above. 
 
3.9. Impact of FTY720-P treatment on IL-1β and PP2A expression and IL-1β production in 
MSU-treated primed THP-1 macrophages 
A total of 500,000 THP-1 monocytes were plated per well in 6-well plates. Monocytes were 
primed with UA and LPS for 24 hours at 37°C as described above.  Cells were treated with MSU 
crystals (100μg/mL) for 6 hours with and without pre-incubation with FTY720-P (3 hours; 
2.5μM). After incubation, cells were collected, centrifuged at 3,000 rpm for 5 minutes to be 
pelleted. Supernatants were collected and stored at -20°C.  RNA isolation, cDNA synthesis and 
qPCR were performed as described above.  Genes of interest included PP2Ac and IL-1β using 
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GAPDH as a reference gene.  IL-1β levels in media supernatants were quantified as described 
above.   
 
 
3.10. Impact of FTY-720-P on THP-1 cell viability 
To rule out the possibility that FTY720-P’s effect is due to a cytotoxic effect on THP-1 
monocytes, monocytes (25,000/well) were seeded in 96-well plate in 100μL per well in triplicate 
wells as the following groups: background (100μL culture medium), low background (100μL 
culture medium and monocytes), positive control (100μL culture medium and monocytes with 10 
μL Cell Lysis Solution), experimental groups including MSU± FTY720-P and MSU (UA+LPS)± 
FTY720-P. Priming was done with UA and LPS as described above for 24 hours.  Cell 
cytotoxicity was determined using lactate dehydrogenase (LDH) Assay Kit (Abcam; ab65393, 
USA).  Cells were pre-incubated with FTY720-P for 3 hours then treated with MSU crystals for 
6 hours. Then cell lysis solution was added to positive control and incubated for ten minutes. The 
microtiter plate was centrifuged at 600xg for ten minutes then clear medium solution (10μL/well) 
was transferred into optically clear 96-well plate. The LDH reaction mix (100μL/well) was 
added to quantify the release of intracellular LDH, which occurs upon damage to cell membrane. 
Absorbance of all controls and samples was at 450nm and the formula used to calculate percent 
cell cytotoxicity was: Cytotoxicity (%) = ((Test Sample – Low Control)/ (High Control – Low 
Control))*100. 
 
3.11. Statistical Analyses 
Statistical analyses of gene expression data were performed using ΔCt values (Ct target gene-Ct 
GAPDH) for each gene of interest in each experimental group.  Continuous variables were 
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initially evaluated whether they satisfied the requirements for parametric statistical tests.  
Statistical significance comparing two groups or multiple groups with parametric data was 
assessed by Student’s t test or ANOVA followed by post-hoc multiple comparisons using 
Tukey’s post-hoc test.  Statistical significance comparing two groups or multiple groups with 
nonparametric data was assessed by Rank Sum test or ANOVA on the ranks.  A p value of < 
0.05 was considered statistically significant.  Data are presented as scatter plots with mean and 
standard deviations highlighted.  Data were generated from at least 3 independent experiments 
with duplicate wells per treatment. 
 
 4. Results 
 
 
4.1. Impact of UA+LPS priming on phagocytosis of fluorescent beads and MSU crystals by 
THP-1 monocytes 
Using the fluorescent beads phagocytosis assay, we observed that priming with LPS alone or 
LPS + UA increased bead 
phagocytosis by THP-1 
monocytes.  Representative 
flow cytometry plots depict 
increased shift of fluorescently 
labeled cell population in LPS-
treated and LPS + UA-treated 
THP-1 monocytes compared to 
control unprimed cells (figure 
Figure 8 Impact of soluble uric acid and lipopolysaccharide 
priming on phagocytosis of FIT-C labeled beads by THP-1 
monocytes.  A) Representative flow cytometry scatter plots 
showing enhanced latex beads phagocytosis (as shown by more 
cells with increased side scatter in P2 region of interest) by THP-1 
monocytes. B) Quantitative determination of beads phagocytosis 
using % positive cells in P2 region of interest. Priming of 
monocytes with LPS and UA significantly increased beads 
phagocytosis by THP-1 monocytes.  *p<0.001, **p<0.01.  
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8A).  The enhancement in cell phagocytic behavior appeared to be due to LPS priming as 
phagocytosis of beads by UA-primed monocytes was not different (p>0.05) from beads’ 
phagocytosis by control cells (figure 8B).  On the other hand, LPS alone or LPS + UA-
primed monocytes exhibited significantly higher (p<0.001) phagocytic activity against 
fluorescent beads compared to control untreated monocytes (figure 8B). 
 
Representative flow cytometry plots of MSU phagocytosis by THP-1 monocytes under 
control and UA and LPS priming conditions are presented in figure 9A.  UA and LPS 
priming appeared to enhance MSU phagocytosis by THP-1 monocytes as illustrated by an 
increase in the percentage of THP-1 monocytes in the P2 region of interest compared to 
control unprimed monocytes.  THP-1 monocytes did not exhibit a significant ability to 
phagocytose MSU crystals (p>0.05) (figure 9B).  However, UA and LPS priming increased 
MSU phagocytosis by THP-1 monocytes compared to unprimed monocytes (p<0.001; 
p<0.01 respectively).  A combination of UA + LPS priming increased MSU phagocytosis by 
THP-1 monocytes and that effect was not significantly different from UA priming alone.      
 
Figure 9 Impact of soluble uric acid and 
lipopolysaccharide priming on phagocytosis 
of monosodium urate (MSU) crystals by 
THP-1 monocytes.  A) Representative flow 
cytometry scatter plots showing enhanced 
MSU crystal phagocytosis (as shown by 
more cells with increased side scatter in P2 
region of interest) by THP-1 monocytes. B) 
Quantitative determination of MSU 
phagocytosis using % positive cells in P2 
region of interest. Priming of monocytes with 
LPS and UA significantly increased MSU 
phagocytosis by THP-1 monocytes.  
*p<0.001, **p<0.01.  
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4.2. Impact of UA + LPS priming on intracellular PP2A activity, IL-1β expression and 
production 
 
Following priming with UA and LPS and subsequent treatment with MSU crystals for 6 
hours, PP2A activity was significantly lower compared to UA+LPS (p<0.05) (figure 10A). 
In contrast, UA + LPS priming did not alter intracellular PP2A activity compared to control 
monocytes (p<0.05). UA + LPS priming significantly increased IL-1β expression and 
production in MSU stimulated monocytes (p<0.001 for both comparisons) (figure 10B & 
10C respectively). 
 
  
 
 
 
 
 
 
 
Figure 10 Impact of uric acid (UA) and lipopolysaccharide (LPS) priming on protein phoaphstase-2A (PP2A) 
activity, interleukin-1 beta (IL-1β) expression and production in THP-1 monocytes.  A) MSU challenge in 
UA+LPS primed monocytes resulted in a significant reduction in PP2A activity as measured by ability to 
generate phosphate from a phosphorylated peptide substrate. B) IL-1β expression in THP-1 monocytes 
following priming with UA or LPS and MSU challenge for 6 hours.  C) IL-1β production in THP-1 monocytes 
following priming with UA or LPS and MSU challenge for 6 hours.  A combination of LPS and UA priming 
resulted in a significant increase in IL-1β expression and production.   
*p<0.001, **p<0.01, n.s. non-significant. 
 
 23 
4.3. PP2A knockdown using PP2A siRNA and effect of knockdown on IL-1beta 
expression and production 
PP2A knockdown using PP2A siRNA for 24 hours resulted in a significant reduction in 
PP2A expression (figure 11A) compared to scramble siRNA (p<0.001).  The magnitude of 
reduction in PP2A expression was approximately 60%.  PP2A activity following PP2A 
siRNA treatment showed significantly lower PP2A activity in knockdown cells compared to 
control and scramble siRNA (figure 11B). In PP2A-knockdown monocytes, MSU treatment 
resulted in a significant increase in IL-1β expression and production compared to untreated 
and scramble siRNA-treated THP-1 monocytes (p<0.05 for both comparisons) (figure 11C & 
11D). 
 
 
 
 
 
 
 
 
 
Figure 11 Impact of protein phosphatase-2A (PP2A) silencing on monosodium urate monohydrate (MSU) 
crystal -induced interleukin-1 beta (IL-1β) expression and production by human THP-1 monocytes.   
A) PP2Ac expression in THP-1 monocytes after PP2A siRNA knockdown. B) PP2A activity in THP-1 
monocytes following PP2A siRNA knockdown. PP2A knockdown resulted in a reduction in PP2A activity. C) 
IL-1β expression in THP-1 monocytes following PP2A knockdown and MSU challenge for 6 hours.  D) IL-1β 
production in THP-1 monocytes following PP2A knockdown and MSU challenge. PP2A knockdown enhanced 
IL-1beta expression and production in comparison to control and scramble stimulated with MSU crystals. 
*p<0.001, **p<0.01, n.s. non-significant. 
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4.4. PP2A activation by FTY720 and FTY720-P at different time-points and FTY720-P 
enhancement of PP2A activity of primed monocytes 
The PP2A activity was determined at 1, 3, 6 and 24 following incubation with prodrug 
FTY720 or active metabolite FTY720-P (figure 12A and 12B).  The peak activity for 
prodrug was at 6 hours incubation while peak activity of the active metabolite was at 3 hours 
after addition to monocytes (figure 12A and 12B). Priming of monocytes using UA and LPS 
resulted in significantly reduced PP2A activity compared to control (p<0.01) and this 
reduction was reversed by the addition of PP2A activating drug FTY720-P (p<0.05) (figure 
12C).  
 
 
 
 
 
 
 
 
 
Figure 12 Impact of fingolimod prodrug (FTY720) and active phosphate metabolite (FTY720-P) treatments on 
intracellular protein phosphatase-2A (PP2A) activity in THP-1 monocytes.  A) PP2A activity in FTY-720- 
treated monocytes. B) PP2A activity in FTY720-P-treated monocytes. The highest activity of FTY720 was at 6 
hours while FTY720-P had peak activity after 3 hours. C) PP2A activity in THP-1 monocytes following 
priming with UA or LPS and challenge with MSU ± FTY720-P pre-incubation for 3 hours. The significant 
reduction in PP2A activity in primed monocytes was reversed by the addition of FTY720-P.  PP2A activity was 
determined by its ability to generate phosphate from a phosphorylated peptide substrate. *p<0.001, **p<0.01; 
***p<0.05. 
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4.5. Impact of FTY720-P on cell viability, PP2A expression, IL-1β expression and 
production in human THP-1 monocytes 
The impact of FTY720-P treatment on THP-1 monocyte viability, PP2Ac expression and IL-1β 
expression and production in UA + LPS primed and MSU treated THP-1 monocytes are 
presented in figure 13.  There was no significant increase in cell cytotoxicity as a result of 
FTY720-P treatment (figure 13A) and FTY720-P treatment did not change the gene expression 
level of PP2Ac (figure 13B).  In contrast, FTY720-P treatment reduced IL-1β expression 
(p<0.001) (figure 13C) and mature IL-1β production (p<0.001) (figure 13D) in UA+LPS pre-
treated human monocytes following MSU stimulation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 Impact of fingolimod phosphate (FTY720-P) treatment on THP-1 monocyte viability, expression of 
PP2Ac, IL-1β expression and production in UA + LPS primed and MSU stimulated monocytes.  *p<0.001; 
**p<0.01.  A) FTY720-P treatment did not display significant cell toxicity.  B) FTY720-P treatment did not 
alter PP2Ac gene expression.  C) FTY720-P treatment reduced IL-1β gene expression.  D) FTY720-P treatment 
reduced IL-1β production. 
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 5. Discussion 
Gout is a chronic inflammatory disease which had been long associated with hyperuricemia (38). 
In hyperuricemia, MSU crystals are precipitated in articular joints, and are recognized by TLRs 
and subsequently activate the MyD88 NLRP3 pathway releasing caspase-1.  Moreover, MSU 
crystals act on NF-kB pathway causing the transcription of the pro-inflammatory cytokine pro-
IL-1β which is cleaved by caspase-1 to IL-1β  that is released from immune cells via exocytosis 
(39). LPS plays an important role in inflammation through its agonistic activity on TLR4 
receptor stimulating the NLRP3 pathway (40).  The role of hyperuricemia as an inflammatory 
signal had been controversial.  A study had shown that uric acid has a dual role as anti-oxidant 
and pro-oxidant (41).  On the other hand, other studies associated hyperuricemia with co-
morbidities involving oxidative stress suggesting that the inflammatory mechanism of 
hyperuricemia is caused by redox imbalance (42) or stimulation of TLR.  Current available 
treatments for gout include colchicine, NSAIDs, corticosteroids and IL-1b receptor antagonists 
and despite their different modes of action, they all had serious adverse effects with no 
remarkable efficiency (43).  Therefore, gout remains a research area of interest. 
 
Protein phosphatase-2A (PP2A) is a heterotrimeric enzyme, which plays an important role in 
intracellular inflammatory pathways through its dephosphorylating key proteins in cell signaling 
cascades.  Although it was studied intensively for its role in cancer as a potential therapeutic 
target (44), some emerging studies focused on its potential anti-inflammatory role via reducing 
the production of pro-inflammatory cytokines TNF-alpha and IL-6 following TLR4 agonistic 
activity by LPS (30). The activity of PP2A is regulated through the inhibitory enzyme SET 
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which is bound to the catalytic subunit of PP2A preventing it from interacting with other 
intracellular components (45).   
 
The most popular PP2A activating drug (PAD) is fingolimod (FTY720) which is present in two 
forms including: fingolimod hydrochloride prodrug (FTY720) and its active metabolite 
following intracellular phosphorylation by sphingosine kinase-2; fingolimod phosphate 
(FTY720-P).  FTY720-P binds to SET releasing PP2A therefore rendering it active. Recent 
studies focused on FTY720-P’s potential anti-inflammatory role by reducing release of IL-8 
(35).  In our study, we investigated the priming role of UA and LPS on THP-1 monocytes 
through MSU phagocytosis and subsequent activation of NF-kB and NLRP3 pathways resulting 
in expression and production of pro-inflammatory cytokine IL-1b and associating this with the 
reduction in PP2A activity.  In addition, FTY720-P was used as a PAD to enhance PP2A activity 
and investigate whether PP2A activation produced an anti-inflammatory effect in our crystal-
induced inflammation in vitro model.  
 
We found that UA and LPS primed monocytes and enhanced phagocytosis of MSU crystals. 
Phagocytic activation of monocytes was confirmed using fluorescent FIT-C labeled latex beads. 
The priming of UA and LPS also enhanced phagocytosis of beads compared to control. 
However, unlike MSU crystals, higher bead phagocytosis was seen with LPS alone compared to 
UA alone.  This could be due to the higher precipitation of MSU crystals with UA due to similar 
chemical composition, which didn’t happen with the beads.  In both cases, the dual activating 
effect of UA and LPS surpassed either of them alone. 
Priming corresponded with higher expression and production of the pro-inflammatory cytokine 
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IL-1b following MSU phagocytosis.  This could be due to the stimulation of NLRP3 and NF-kB 
pathways.  Intracellular PP2A activity was not found to decrease with priming alone but after the 
phagocytosis of MSU crystals.  This might be due to the dual signaling needed by the 
inflammatory pathway through both NLRP3 and NF-kB.  The association of enhanced 
expression and production of IL-1b with a decrease in PP2A activity suggests that PP2A plays a 
role in in inflammation.  The role of PP2A was further investigated by knocking down PP2Ac 
gene using PP2Ac siRNA.  PP2A expression decreased with PP2A knockdown and this was 
associated with a decrease in PP2A activity.  In unprimed monocytes after PP2A knockdown and 
MSU challenge, there was higher expression of IL-1b compared to control monocytes as well as 
enhanced IL-1b production. This confirms the previous association between the decrease of 
PP2A activity and increased severity of inflammation. 
  
We further compared PP2A activation in THP-1 monocytes using the FTY720 prodrug and the 
active metabolite FTY720-P at different time points.  The peak activity for FTY720 was 
observed at 6 hours while the peak activity for FTY720-P occurred at 1 hour.  This is attributed 
to the metabolism of FTY720 since it takes about 6 hours to get uptaken into monocytes and 
phosphorylated by the intracellular sphingosine kinase-2 into FTY720-P, the active form of the 
drug.  In case of FTY720-P, the addition of the active metabolite resulted in a quicker effect on 
PP2A activity.  FTY720-P was therefore used as our PP2A activating drug in follow-up studies. 
In monocytes primed with UA and LPS, the decreased PP2A activity was reversed by the pre-
incubation of cells with FTY720-P for 3 hours prior to MSU challenge affirming the PP2A 
restoring activity of FTY720 especially with primed monocytes.  Furthermore, in primed 
monocytes, the higher expression and release of IL-1b was reversed by pre-incubation with 
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FTY720-P.  This confirms the anti-inflammatory role of FTY720-P through its action as a PP2A 
activating drug.  Interestingly, PP2A activation was not due to an increased PP2A intracellular 
pool as FTY720-P treatment showed no significant effect on PP2A expression in primed cells 
compared to control.  Finally, LDH cytotoxicity assay showed no significant cellular death 
confirming that all results aren’t caused by cellular death due to priming or due to addition of 
FTY720-P. 
 
 6. Conclusions 
We conclude that priming THP-1 monocytes using UA and LPS results in higher MSU 
phagocytosis and subsequently higher expression and production of IL-1b with decreased PP2A 
activity.  Increasing PP2A activity through PADs as FTY720-P can reverse the pro-inflammatory 
effect of priming.  PP2A is a novel target in gout. 
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